SP 500 Recovers as Tech Surge Offsets Energy Rout Dow Slips NATO Defense Spending Surge and US Troop Deployment to Poland Signal Heightened Military Focus Evercore ISI Adjusts Outlook for Illinois Tool Works Price Target Revised Lower Estate Battle Exposes Transparency Crisis in Family Wealth Management Ferrari Luce EV Faces Market Scrutiny After Social Media Backlash Trumps 230M Legal Claim Raises Governance Concerns and Market Stability Questions MSTR Q1 2026 Earnings EPS Falls Far Short of Estimates Stock Declines Performance Shipping Inc PSHG Q4 2025 Earnings EPS Beats Estimates Amid Shipping Market Headwinds UFPI Q1 2026 Earnings EPS Falls Short as Cost Pressures Mount OLOX Q3 2023 Earnings NarrowerthanExpected Loss Drives 3736 EPS Surprise KNSA Q1 2026 Earnings EPS Surpasses Estimates by 315 Despite Stock Decline Georgia Power Preferred Notes GPJA Edge Lower Amid Cautious Trading Tiziana Life Sciences TLSA Slips 265 as Stock Tests Key Support Zone Thornburg Income Builder Opportunities Trust TBLD Gains 22 as IncomeFocused Funds Find Favor Oaktree Acquisition Corp III Life Sciences Units OACCU Slip 25 Support Levels in Focus Permian Basin Royalty Trust Slips 7 Key Levels Under Pressure Ituran ITRN Rallies to 5929 Key Resistance Level in Focus Sana Biotechnology Slides 25 as SANA Tests Crucial Support Zone Churchill Capital Corp IX CCIX Holds Steady Near Support as Market Awaits Merger Catalyst Immuneering Corporation IMRX Gains Ground Bulls Test Key Resistance at 566 Organon Co OGN Holds Steady Near Support as Market Digests Flat Trading Session Enhanced Games Inside the Controversial Steroid Olympics Backed by Donald Trump Jr RR Earnings Overview 20260528 Tiptree Inc TIPT Q2 2025 Earnings Solid EPS Performance Despite Revenue Opacity Rapid7 Q1 2026 Earnings EPS Surprise Drives Positive Market Response EXK Q1 2026 Earnings Strong Earnings Beat Despite Negative Stock Reaction ORN Q1 2026 Earnings EPS Surprises Positively Revenue Uncertainty Weighs on Shares Blackbaud Q1 2026 Earnings Modest EPS Beat Reflects Steady Execution BHFAP Q1 2026 Earnings EPS Falls Short of Estimates Preferred Stock Declines NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43